248,322 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Eagle Health Investments LP

Eagle Health Investments LP acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 248,322 shares of the company's stock, valued at approximately $30,439,000. Protagonist Therapeutics comprises about 5.0% of Eagle Health Investments LP's portfolio, making the stock its 8th biggest position. Eagle Health Investments LP owned about 0.39% of Protagonist Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PTGX. BlackRock Inc. purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter worth approximately $1,263,535,000. Vanguard Group Inc. boosted its stake in shares of Protagonist Therapeutics by 27.2% during the 4th quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company's stock worth $472,832,000 after purchasing an additional 1,156,461 shares during the period. State Street Corp boosted its stake in shares of Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company's stock worth $177,281,000 after purchasing an additional 500,924 shares during the period. Wellington Management Group LLP grew its holdings in Protagonist Therapeutics by 66.2% during the 4th quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company's stock valued at $276,992,000 after purchasing an additional 1,262,977 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Protagonist Therapeutics by 9.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company's stock worth $304,866,000 after purchasing an additional 241,546 shares during the period. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 34,239 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $148.52, for a total transaction of $5,085,176.28. Following the completion of the sale, the chief executive officer owned 523,478 shares of the company's stock, valued at approximately $77,746,952.56. The trade was a 6.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director owned 7,825 shares of the company's stock, valued at approximately $922,880.50. The trade was a 53.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 127,000 shares of company stock valued at $17,818,139 over the last quarter. Insiders own 5.19% of the company's stock.

Wall Street Analyst Weigh In

PTGX has been the subject of several recent analyst reports. Barclays boosted their target price on Protagonist Therapeutics from $151.00 to $153.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. The Goldman Sachs Group upgraded Protagonist Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $110.00 to $186.00 in a report on Monday, August 10th. Citizens Jmp raised their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a "market outperform" rating in a research note on Wednesday, May 6th. Wall Street Zen cut Protagonist Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Truist Financial increased their target price on Protagonist Therapeutics from $145.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $140.53.

Protagonist Therapeutics Price Performance

Shares of NASDAQ PTGX opened at $154.94 on Thursday. Protagonist Therapeutics, Inc. has a 1-year low of $54.50 and a 1-year high of $160.81. The business has a fifty day moving average price of $132.99 and a 200 day moving average price of $109.36. The stock has a market capitalization of $10.03 billion, a P/E ratio of 150.43 and a beta of 1.78.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The company had revenue of $213.47 million for the quarter, compared to analyst estimates of $212.03 million. The company's revenue for the quarter was up 3746.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 4.22 earnings per share for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc NASDAQ: PTGX is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source